TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02559752

Intervention type: OTHER
Intervention: NIH Toolbox Cognitive Battery
Description: * For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~* For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning.
Study: NCT01970982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS 2.2)
Description: THS 2.2 ad libitum for 5 days in confinement

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking abstinence (SA)
Description: SA for 5 days in confinement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette (CC)
Description: Subject's own preferred brand of CC ad libitum for 5 days in confinement
Study: NCT03270605

Intervention type: PROCEDURE
Intervention: Myomectomy
Description: Surgical removal of uterine fibroid
Study: NCT02565043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RENASYS TOUCH Negative Pressure Wound Therapy System
Description: RENASYS TOUCH NPWT System was administered to all participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RENASYS TOUCH Negative Pressure Wound Therapy System
Description: RENASYS TOUCH NPWT System was administered to all participants.
Study: NCT03521596

Intervention type: OTHER
Intervention: MRD and clonal evolution
Description: Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
Study: NCT01310387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active pain management
Description: Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
Study: NCT01358695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ANT-1207
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.
Study: NCT01191164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation Utilizing Permanent Breast Seed Implant
Description: Target Volumes: The surgical cavity will be assessed with US \& CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre.
Study: NCT01984684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delafloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aztreonam
Study: NCT01175603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)
Description: 6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
Study: NCT02707835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self massage
Description: self massage, skin care education, manual lymph drainage exercise, compression garment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual lymph drainage
Description: manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: epidermis fascia taping
Description: epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
Study: NCT03152526

Intervention type: DEVICE
Group type: OTHER
Intervention: Interventions
Description: CliniMACS® CD3 and CD19 Reagent System
Study: NCT02371954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy Older Latinos are Active
Description: Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fotonovela
Description: Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
Study: NCT04310592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study: NCT03271281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Following injection of 68Ga-NODAGA-E\[c(RGDyK)\]2 the patients will be subjected to whole body PET/CT
Study: NCT02218437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC+ATG
Description: MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
Study: NCT03656536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
Study: NCT02395042

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS Placebo
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS Placebo
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
Study: NCT02040051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sound isolation / Music therapy
Description: Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sound isolation / Music therapy
Description: Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)
Study: NCT01861899

Intervention type: DEVICE
Intervention: SI-LOK
Description: Sacro-iliac joint fusion
Study: NCT00447603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Losartan/HCTZ
Description: losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Losartan/HCTZ
Description: losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
Study: NCT00655421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided Visual Inspection
Description: Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VelScope
Description: Examination of the oral cavity through a VelScope by trained Primary Health Care Worker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toluidine Blue Assisted Oral Examination
Description: Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
Study: NCT03721939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEX Scoring Catheter
Description: Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
Study: NCT04435366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacincaptad Pegol
Description: Avacincaptad Pegol Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacincaptad Pegol
Description: Avacincaptad Pegol Intravitreal Injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
Study: NCT03696017

Intervention type: OTHER
Intervention: Multi-domain assessment battery
Description: Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.

Intervention type: OTHER
Intervention: Multi-domain assessment battery
Description: Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.

Intervention type: OTHER
Intervention: Multi-domain assessment battery
Description: Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.
Study: NCT03853109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
Study: NCT03575325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
Study: NCT00321711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531 (Romiplostim)
Description: AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531 (Romiplostim)
Description: AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531 (Romiplostim)
Description: AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: hypomethylating agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: hypomethylating agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: hypomethylating agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: hypomethylating agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Decitabine
Description: hypomethylating agent
Study: NCT04211298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be used for sedation during bronchoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol
Study: NCT04398303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACT-20-MSC
Description: 1 million cells / kg body weight in 100 ml in conditioned media

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACT-20-CM
Description: 100 ml of conditioned media only
Study: NCT04495179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Subjects will receive AZD4635 orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Subjects will receive AZD4635 orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Subjects will receive intravenous cabazitaxel every 3 weeks
Study: NCT03707977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Administered by intravenous (IV) infusion
Study: NCT02068807

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein drops
Description: After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose drops
Description: After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
Study: NCT04398303

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of MEM-α
Study: NCT02625896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
Study: NCT03468010

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation
Description: radiation with concurrent ciplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: radiation with concurrent ciplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
Study: NCT02061202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo training inhaler with the same instructions as the experimental group.
Study: NCT01743079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: LdT 600mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: LAM 100mg QD